Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis
High recurrence is a major challenge in treating T-lymphoblastic lymphoma (T-LBL). Allogeneic (allo-) or autologous (auto-) stem cell transplantation (SCT) is recommended to reduce relapse, though the optimal choice remains unclear. This study retrospectively analyzed outcomes in T-LBL patients unde...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2025-06-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849310759183450112 |
|---|---|
| author | Xiaodan Luo Zhiping Fan Runhui Zheng Fen Huang Na Xu Pengfei Qin Jingren Lin Chunyan Wang Huiqiang Huang Huo Tan Qifa Liu |
| author_facet | Xiaodan Luo Zhiping Fan Runhui Zheng Fen Huang Na Xu Pengfei Qin Jingren Lin Chunyan Wang Huiqiang Huang Huo Tan Qifa Liu |
| author_sort | Xiaodan Luo |
| collection | DOAJ |
| description | High recurrence is a major challenge in treating T-lymphoblastic lymphoma (T-LBL). Allogeneic (allo-) or autologous (auto-) stem cell transplantation (SCT) is recommended to reduce relapse, though the optimal choice remains unclear. This study retrospectively analyzed outcomes in T-LBL patients undergoing SCT, with 44 patients receiving allo-SCT and 25 receiving auto-SCT. After a median follow-up of 115 months, the 5-year cumulative incidence of relapse (CIR) was 30.4% overall, 28.7% for allo-SCT, and 37.7% for auto-SCT (p = 0.660). Five-year overall survival (OS) was 68.2% for allo-SCT and 64.0% for auto-SCT; progression-free survival (PFS) was 68.2% and 64.0%, respectively (p = 0.580, 0.940). Patients with age-adjusted international prognostic index (aaIPI) ≥3 had a significantly higher relapse rate in the auto-SCT group (p = 0.022). Univariate analysis identified male sex, aaIPI ≥3, non-CR at cycle 4, and non-CR1 at SCT as adverse prognostic factors. Allo-SCT may benefit patients with high aaIPI. |
| format | Article |
| id | doaj-art-cc508f372ffe474fa8d14bf6dd002168 |
| institution | Kabale University |
| issn | 2543-6368 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Blood Science |
| spelling | doaj-art-cc508f372ffe474fa8d14bf6dd0021682025-08-20T03:53:38ZengWolters Kluwer HealthBlood Science2543-63682025-06-0172e0022210.1097/BS9.0000000000000222202506000-00012Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysisXiaodan Luo0Zhiping Fan1Runhui Zheng2Fen Huang3Na Xu4Pengfei Qin5Jingren Lin6Chunyan Wang7Huiqiang Huang8Huo Tan9Qifa Liu10a Hematology Department, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chinab Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Chinaa Hematology Department, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chinab Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Chinab Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Chinac Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chinac Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chinac Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chinad Department of Medical Oncology, State Key Laboratory of Oncology in South China/Cancer Center, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Chinaa Hematology Department, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chinab Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaHigh recurrence is a major challenge in treating T-lymphoblastic lymphoma (T-LBL). Allogeneic (allo-) or autologous (auto-) stem cell transplantation (SCT) is recommended to reduce relapse, though the optimal choice remains unclear. This study retrospectively analyzed outcomes in T-LBL patients undergoing SCT, with 44 patients receiving allo-SCT and 25 receiving auto-SCT. After a median follow-up of 115 months, the 5-year cumulative incidence of relapse (CIR) was 30.4% overall, 28.7% for allo-SCT, and 37.7% for auto-SCT (p = 0.660). Five-year overall survival (OS) was 68.2% for allo-SCT and 64.0% for auto-SCT; progression-free survival (PFS) was 68.2% and 64.0%, respectively (p = 0.580, 0.940). Patients with age-adjusted international prognostic index (aaIPI) ≥3 had a significantly higher relapse rate in the auto-SCT group (p = 0.022). Univariate analysis identified male sex, aaIPI ≥3, non-CR at cycle 4, and non-CR1 at SCT as adverse prognostic factors. Allo-SCT may benefit patients with high aaIPI.http://journals.lww.com/10.1097/BS9.0000000000000222 |
| spellingShingle | Xiaodan Luo Zhiping Fan Runhui Zheng Fen Huang Na Xu Pengfei Qin Jingren Lin Chunyan Wang Huiqiang Huang Huo Tan Qifa Liu Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis Blood Science |
| title | Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis |
| title_full | Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis |
| title_fullStr | Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis |
| title_full_unstemmed | Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis |
| title_short | Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis |
| title_sort | superiority of allo sct to auto sct in high risk t cell lymphoblastic lymphoma leukemia patients with aaipi ≥3 insights from a retrospective multicenter analysis |
| url | http://journals.lww.com/10.1097/BS9.0000000000000222 |
| work_keys_str_mv | AT xiaodanluo superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT zhipingfan superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT runhuizheng superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT fenhuang superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT naxu superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT pengfeiqin superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT jingrenlin superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT chunyanwang superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT huiqianghuang superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT huotan superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis AT qifaliu superiorityofalloscttoautosctinhighrisktcelllymphoblasticlymphomaleukemiapatientswithaaipi3insightsfromaretrospectivemulticenteranalysis |